Novel metabotropic glutamate receptor 4 and glutamate receptor 8 therapeutics for the treatment of anxiety

Expert Opinion on Investigational Drugs

Volumn 24, Issue 4, 2015, Pages 519-528

  Raber, Jacob ^a   Duvoisin, Robert M ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Allosteric modulators; Anxiety; Fear learning; Metabotropic glutamate receptor

Indexed keywords

GLUTAMATE RECEPTOR 4; METABOTROPIC RECEPTOR 8; ANXIOLYTIC AGENT; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 4;

ANXIETY DISORDER; DRUG TARGETING; HUMAN; NEUROTRANSMITTER RELEASE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; ANIMAL; ANXIETY DISORDERS; DRUG DESIGN; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84924753036     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.986264     Document Type: Review

References (82)

1. Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995;34:1-26
2. Vaidya A, Jain S, Jain A, et al. Metabotropic glutamate receptors: a review on prospectives and therapeutic aspects. Mini Rev Med Chem 2013;13:1967-81
3. Bezerra de Menezes G, Fontenelle L, et al. Treatment-resistant anxiety disorders: social phobia, generalized anxiety disorder and panic disorder. Rev Bras Psiquiatr 2007;29:S55-60
4. Lanouette N, Stein M. Advances in the management of treatment-resistant anxiety disorders. Focus 2010;8:501-24
5. Polack M, Otto M, Roy-Bynne P, et al. Novel treatment approaches for refractory anxiety disorders. Depress Anxiety 2008;25:467-76
6. Grillon C, Cordova J, Levine LR, et al. Anxiolytic effects of a novel group ii metabotropic glutamate receptor agonist (ly354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl) 2003;168:446-54
7. Schoepp D, Wright R, Levine L, et al. Ly354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 2003;6:189-97
8. Paluchaa A, Pilc A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther 2007;115:116-47
9. Linden AM, Johnson BG, Peters SC, et al. Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor. Neuropharmacology 2002;43:251-9
10. Duvoisin R, Zhang C, Pfankuch T, et al. Increased measures of anxiety and weight gain in mice lacking the group iii metabotropic glutamate receptor mGlur8. Eur J Neurosci 2005;22:425-36
11. Gosnell H, Silberman Y, Grueter B, et al. Mglur8 modulates excitatory transmission in the bed nucleus of the stria terminalis in a stress-dependent manner. Neuropsychoparmacology 2011;36:1599-607
12. Duvoisin R, Villasana L, Davis M, et al. Opposing roles of mGlur8 in measures of anxiety involving non-social and social challenges. Behav Brain Res 2011;221:50-4
13. Davis M, Iancu O, Acher F, et al. Role of mGlur4 in acquisition of fear learning and memory. Neuropharmacology 2013;55:365-72
14. Davis M, Haley T, Duvoisin R, et al. Measures of anxiety, sensorimotor function, and memory in male and female mGlur4-/-mice. Behav Brain Res 2012;229:21-8
15. Duvoisin R, Pfankuch T, Wilson J, et al. Acute pharmacological modulation of mGlur8 reduces measures of anxiety. Behav Brain Res 2010;212:168-73
16. Kalinichev M, Le Poul E, Bolea C, et al. Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 adx88178 in rodent models of neuropsychiatric disorders. J Pharmacol Exp Ther 2014;350:495-505
17. Mercier M, Lodge D. Group iii metabotropic glutamate receptors: pharmacology, physiology, and therapeutic potential. Neurochem Res 2014;39:1876-94
18. Becker JA, Clesse D, Spiegelhater C, et al. Autistic-like syndrome in mu opioid receptor null mice is relieved by facilitated mGlur4 activity. Neuropsychoparmacology 2014;39(9):2049-60
19. Lopez S, Turle-Lorenzo N, Acher F, et al. Targeting group iii metabotropic glutamate receptors produces complex behavioral effects in rodent models of parkinson's disease. J Neurosci 2007;27:6701-11
20. Hopkins C, Lindsley C, Niswender C. Mglur4-positive allosteric modulation as potential treatment for parkinson's disease. Future Med Chem 2009;1:501-13
21. Snead OC III, Banerjee PK, Burnham M, et al. Modulation of absence seizures by the gaba(a) receptor: a critical role for metabotropic glutamate receptor 4 (mGlur4). J Neurosci 2000;20:6218-24
22. Fallarino F, Volpi C, Fazio F, et al. Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nat Med 2012;16:897-903
23. Takaki H, Kikuta R, Shibata H, et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 8 gene (grm8) with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004;128B:6-14
24. Corti C, Aldegheri L, Somogyi P, et al. Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGlur4) in the rodent CNS. Neuroscience 2002;110:403-20
25. Tanabe Y, Nomuram A, Masu M, et al. Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGlur3 and mGlur4. J Neurosci 1993;13:1372-8
26. Bradley S, Levey A, Hersch S, et al. Immunocytochemical localization of group iii metabotropic glutamate receptors in the hippocampus with subtype-specific antibodies. J Neurosci 1996;16:2044-56
27. Ohishi H, Akazawa C, Shigemoto R, et al. Distribution of the mrnas for metabotropic glutamate receptors, mGlur4 and mGlur7, in the rat brain. J Comp Neurol 1995;360:555-70
28. Saugstad JA, Kinzie JM, Shinora M. Cloning and expression of rat glutamate receptor 8 reveals a distinct pharmacological profile. Mol Pharmacol 1997;51:119-25
29. Duvoisin R, Zhang C, Ramonell K. A novel metabotropic glutamate receptor expressed in the retina and olfactory bulb. J Neurosci 1995;15:3075-83
30. Malherbe P, Kratzeisen C, Lundstrom K, et al. Cloning and functional expression of alternative spliced variants of the human metabotropic glutamate receptorBrain Res Mol Brain Res 1999;67:201-10
31. Shigemoto R, Kinoshita A, Wada A, et al. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci 1997;17:7503-22
32. Fendt M, Burki H, Imobersteg S. The effect of mGlu8 deficiency in animal models of psychiatric disease. Genes Brain Behav 2010;9:33-44
33. Raber J, Duvoisin R, Grueter B, et al. Age-dependent increases in measures of anxiety of mGlur8-/-mice in anxiety tests involving avoidable and inavoidable anxiety-provoking stimuli. Soc Neurosci Annual Meeting 2007; San Diego, CA; 2007
34. Duvoisin R, Villasana L, Pfankuch T, et al. Sex-dependent cognitive phenotype of mice lacking mGlur8. Behav Brain Res 2010;209:21-6
35. Liang KC, Melia KR, Campeau S, et al. Lesions of the central nucleus of the amygdala, but not the paraventricular nucleus of the hypothalamus, block the excitatory effects of corticotropinreleasing factor on the acoustic startle reflex. J Neurosci 1992;12:2313-20
36. Pekhletski R, Gerlai R, Overstreet LS, et al. Impaired cerebellar synaptic plasticity and motor performance in mice lacking the mGlur4 subtype of metabotropic glutamate receptor. J Neurosci 1996;16:6364-73
37. Grillon C, Davis M. Fear-potentiated startle conditioning in humans: explicit and contextual cue conditioning following paired versus unpaired training. Psychophysiology 1997;34:451-8
38. Mineka S, Oehlberg K. The relevance of recent developments in classical conditioning to understanding the etiology and maintenance of anxiety disorders. Acta Psychol(Amst) 2008;127:567-80
39. Phelps E, Delgrado M, Nearing K, et al. Extinction learning in humans: role of the amygdala and vmpfc. Neuron 2004;43:897-905
40. Johansen JP, Hamanaka H, Monfils MH, et al. Optical activation of lateral amygdala pyramidal cells instructs associative fear learning. Proc Natl Acad Sci USA 2010;107:12692-7
41. Morgan M, LeDoux J. Contribution of ventrolateral prefrontal cortex to the acquisition and extinction of conditioned fear in rats. Neurobiol Learn Mem 1999;72:244-51
42. Quirk GJ, Garci R, Gonzalez-Lima F. Prefrontal mechanisms in extinction of conditioned fear. Biol Psychiatry 2006;60:337-43
43. Iscru E, Goddyn H, Ahmed T, et al. Improved spatial learning is associated with increased hippocampal but not prefrontal long-term potentiation in mGlur4 knockout mice. Genes Brain Behav 2013;12:615-25
44. Davis M, Duvoisin R, Raber J. Related functions of mGlur4 and mGlur8. Pharmacol Biochem Behav 2013;111:11-16
45. Lin C, Lee C, Huang Y, et al. Activation of group ii metabotropic glutamate receptors induces depotentiation in amygdala slices and reduces fearpotentiated startle in rats. Learn Mem 2005;12:30-137
46. Rush A, Wu J, Rowan M, Anwyl R. Activation of group ii metabotropic glutamate receptors results in long-term potentiation following preconditioning stimulation in the dentate gyrus. Neuroscience 2001;105:335-41
47. Neugebauer V, Keele N, Shinnick-Gallagher P. Loss of longlasting potentiation mediated by group iii mGlurs in amygdala neurons in kindlinginduced epileptogenesis. J Neurophysiol 1997;78:3475-8
48. Neugebauer V, Zinebi F, Russell R, et al. Cocaine and kindling alter the sensitivity of group ii and iii metabotropic glutamate receptors in the central amygdala. Am J Physiol 2000;22:759-70
49. Schrader LA, Tasker JG. Presynaptic modulation by metabotropic glutamate receptors of excitatory and inhibitory synaptic inputs to hypothalamic magnocellular neurons. J Neurophysiol 1997;77:527-36
50. Grueter B, Winder D. Group ii and iii metabotropic glutamate receptors suppress excitatory synaptic transmission in the dorsolateral bed nucleus of the stria terminalis. Neuropsychopharmacology 2005;30:1302-11
51. Campogna M. Distinct properties of presynaptic group ii and iii metabotropic glutamate receptor-mediated inhibition of perforant pathway-CA1 EPSCs. Eur J Neurosci 2004;19:2847-58
52. Wieronska JM, Stachowicz K, Acher F, et al. Opposing efficacy of group iii mGlu receptor activators, lsp1-2111 and amn082, in animal models of positive symptoms of schizophrenia. Psychoparmacology 2012;220(3):481-94
53. Mercier M, Lodge D, Fang G, et al. Characterization of an mGlu8 receptorselective agonist and antagonist in the lateral and medial perforant path inputs to the dentate gyrus. Neuropharmacology 2013;67:294-303
54. Stachowicz K, Klak K, Klodzinska A, et al. Anxiolytic-like effects of phccc, an allosteric modulator of mGlu4 receptors, in rats. Eur J Pharmacol 2004;498:153-6
55. Wieronska JM, Szewszyk B, Palucha A, et al. Anxiolytic action of group ii and group iii metabotropic glutamate receptors agonist involves neuropeptide y in the amygdala. Pharmacol Rep 2005;57:734-43
56. Palucha A, Tatarczynska E, Branski P, et al. Group iii mGlu receptor agonists produce anxiolytic-and antidepressantlike effects after central administration in rats. Neuropharmacology 2004;46:151-9
57. Beurrier C, Lopez S, Revy D, et al. Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J 2009;23:3619-28
58. Wieronska JM, Stachowicz K, Palucha-Poniewiera A, et al. Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABA-ergic systems. Neuropharmacology 2010;59:627-34
59. LePoul E, Campo B, Bolea C, et al. Validating the role of mGlur4 receptors in the pathophysiology of anxiety using selective mGlur4 positive allosteric modulators. Soc Neurosci Annual Meeting 2010; San Diego, CA; 2010. Available from: http://www. addexpharma.com/fileadmin/user-upload/Conference-slideshows/mGluR4-anxiety-Poster-SfN-2010.pdf
60. Campo B. Role of mGlur4 receptors in anxiety disorders. Soc Neurosci Annual Meeting 2010; San Diego, CA; 2010.Available from: http://www. addexpharma.com/fileadmin/user-upload/Conference-slideshows/mGluR4-anxiety-Allost-Modul- Congress-San-Diego2010-V3-.pdf
61. Raber J, Villasana L, Pfankuch T, et al. Opposing roles of mGlur8 in measures of anxiety and social interaction. Soc Neurosci Annual Meeting 2010; San Diego, CA; 2010
62. Linden AM, Bergeron M, Baez M, et al. Systemic administration of the potent mGlu8 receptor agonist (s)-3,4-dcpg induces c-fos in stress-related brain regions in wild-type, but not mGlu8 receptor knockout mice. Neuropharmacology 2003;45:473-83
63. Tye KM, Prakash R, Kim SY, et al. Amygdala circuitry mediating reversible and bidirectional control of anxiety. Nature 2011;471:358-62
64. Pape H-C, Pare D. Plastic synaptic networks of the amygdala for the acquisition, expression, and extinction of conditioned fear. Phys Rev 2010;90:419-63
65. Milad M, Orr S, Pittman R, et al. Context modulation of memory for fear extinction in humans. Psychophysiology 2005;42:456-64
66. Huff N, Hernandez J, Fecteau M, et al. Revealing context-specific conditioned fear memories with full immersion virtual reality. Front Behav Neurosci 2011;5:75
67. Domino E, French J, Pohorecki R, et al. Further observation on the effects of subhyponotic doses of midazolam in normal volunteers. Psychoparmacol Bull 1989;25:460-5
68. Gupta A, Lind S, Eklund A, et al. The effects of midazolam and flumazenil on psychomotor function. J Clin Anesth 1997;9:21-5
69. Schlegel S, Steinert H, Bockisch A, et al. Decreased benzodiazepine receptor binding in panic disorder measured by iomazenil-spect. A preliminary report. Eur Arch Psychiatry Clin Neurosci 1994;244:49-51
70. Kaschka W, Feistel H, Ebert D. Reduced benzodiazepine receptor binding in panic disorder measured by iomazenil spect. J Psychiatr Res 1995;29:427-34
71. Roy-Byrne P, Wingerson D, Radant A, et al. Reduced benzodiazepine sensitivity in patients with panic disorder: comparison with patients with obsessivecompulsive disorder and normal subjects. Am J Psychiatry 1996;153:1444-9
72. Glue P, Nutt D. Benzodiazepine receptor sensitivity in panic disorder. Lancet 1991;337:563
73. Cowley D, Ha E, Roy-Byrne P. Determinants of pharmacologic treatment in panic disorder. J Clin Psychiatry 1997;58:555-61
74. Malizia A, Cunningham V, Bell C, et al. Decreased GABA (a)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 1998;55:715-20
75. Bremner J, Innis R, Southwick S, et al. Decreased benzodiazepine receptor binding in prefrontal cortex in combatrelated posttraumatic stress disorder. Am J Psychiatry 2000;157:1120-6
76. Woods J, Katz J, Winger G. Benzodiazepines: use, abuse, and consequence. Pharmacol Rev 1992;44:151-347
77. Grynpore R, Mitenko P, Sitar D, et al. Drug-associated hospital admissions in older medical patients. J Am Geriatr Soc 1988;36:1092-8
78. Sangha S, Narayanan R, Bergado-Acosta J, et al. Deficiency of the 65 kda isoform of glutamic acid decarboxylase impairs extinction of cued but not contextual fear memory. J Neurosci 2009;29:15713-20
79. Horvath S, Zhang B, Carlson M, et al. Analysis of oncogenic signaling networks in glioblastoma indentifies aspm as a molecular target. Proc Natl Acad Sci USA 2006;103:17402-7
80. Langfelder P, Horvath S. Wgcna: an r package weighed correlation network analysis. BMC Bioinformatics 2008;9:559
81. Iancu O, Darakjian P, Walter N, et al. Genetic diversity and striatal gene networks: focus on the heterogeneous stock-collaborative cross mouse. BMC Genomics 2011;11:585
82. Anagnostaras S, Wood S, Shuman T, et al. Automated assessment of Pavlovian conditioned freezing and shock reactivity in mice using the video freeze system. Front Beahv Neurosci 2010;4:1-11